Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP417782.RAzGlnhfGV1c4_oS7sQV8GaRDn_GiptnHeIPo82JNrhhI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP417782.RAzGlnhfGV1c4_oS7sQV8GaRDn_GiptnHeIPo82JNrhhI130_assertion type Assertion NP417782.RAzGlnhfGV1c4_oS7sQV8GaRDn_GiptnHeIPo82JNrhhI130_head.
- NP417782.RAzGlnhfGV1c4_oS7sQV8GaRDn_GiptnHeIPo82JNrhhI130_assertion description "[The frequencies of PMs of CYP2C19 were 34.1%(46/135) in the group of esophagus cancer patients, 31.8%(47/148) in the stomach cancer patients, 34.4%(73/212) in the group of lung cancer patients, only 4.5%(5/112) in the bladder cancer patients and 14.0%(52/372) in control group.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP417782.RAzGlnhfGV1c4_oS7sQV8GaRDn_GiptnHeIPo82JNrhhI130_provenance.
- NP417782.RAzGlnhfGV1c4_oS7sQV8GaRDn_GiptnHeIPo82JNrhhI130_assertion evidence source_evidence_literature NP417782.RAzGlnhfGV1c4_oS7sQV8GaRDn_GiptnHeIPo82JNrhhI130_provenance.
- NP417782.RAzGlnhfGV1c4_oS7sQV8GaRDn_GiptnHeIPo82JNrhhI130_assertion SIO_000772 15222046 NP417782.RAzGlnhfGV1c4_oS7sQV8GaRDn_GiptnHeIPo82JNrhhI130_provenance.
- NP417782.RAzGlnhfGV1c4_oS7sQV8GaRDn_GiptnHeIPo82JNrhhI130_assertion wasDerivedFrom befree-20140225 NP417782.RAzGlnhfGV1c4_oS7sQV8GaRDn_GiptnHeIPo82JNrhhI130_provenance.
- NP417782.RAzGlnhfGV1c4_oS7sQV8GaRDn_GiptnHeIPo82JNrhhI130_assertion wasGeneratedBy ECO_0000203 NP417782.RAzGlnhfGV1c4_oS7sQV8GaRDn_GiptnHeIPo82JNrhhI130_provenance.